ALNY Healthcare

Alnylam Pharmaceuticals, Inc.

$159.89+1.20%

Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 21.4B USD
Enterprise value: 21.1B USD
Full-time employees: 2,500

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback: higher risk than most peers: more debt relative to equity (2.21× vs a peer median of 0.22×)higher risk: more debt vs equity (2.21× vs peers 0.22×)

Ranks #194 of 1,157 healthcare companies (top 17%)

See how it ranks against its peers

Worth knowing

Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
Alnylam Pharmaceuticals made a profit per share in its latest year after a loss the year before.
Operating margin at a 6-year high. 14% in 2025, the best of the last 6 years.
Alnylam Pharmaceuticals kept 14% of revenue as operating profit in 2025, its highest in the 6 years of filings we have.
Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $493M in 2020 to $3.7B in 2025.
Alnylam Pharmaceuticals's fiscal-year revenue rose in each of the five years to 2025, from $493M to $3.7B.
Profit is backed by cash. Free cash flow is 106% of reported profit.
Alnylam Pharmaceuticals's free cash flow is 106% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

StockQuotient Score

67/ 100▲ 3 since Oct 27 close

Oct 5 64 → Nov 4 67 (+3)

Valuation

Is the price right?

60/100

Moderate▲ 9 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why it changed since the Oct 27, 2026 close: Score 51 → 60

Share price -29.5%+5
Peer companies moved+4

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield3.6%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score 1.45Sector median: 0.0148 · MAD: 0.0148

EBITDA yield5.0%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsReported value50% base weight · Z-score 0.25Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield3.8%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield6.3%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

97/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 29.4%

Why

Stronger than most peers on:

▲ Revenue growth
▲ 3-yr revenue
▲ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a loss to a profit33% base weight · Z-score 4.46Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth57.2%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 6.11Sector median: 0.0584 · MAD: 0.0840

Revenue growth95.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 9.14Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

97/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Operating margin rose 7.3 points to 20.8%

Why

Stronger than most peers on:

▲ ROIC
▲ ROA
▲ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin20.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 1.13Sector median: 0.0706 · MAD: 0.1217

Return on assets13.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 2.29Sector median: 0.0166 · MAD: 0.0537

Return on invested capital65.8%

Yahoo Finance fallback · SEC operating income or invested capital unavailable · trailing 12 monthsOutlier capped at sector 5th/95th percentile33% base weight · Z-score 3.81Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin79.8%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity57.2%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.27

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 1.05Sector median: 0.6250 · MAD: 0.3380

Current ratio3.05×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.34Sector median: 2.5860 · MAD: 1.3850

Debt / equity2.21×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score -9.73Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Alnylam Pharmaceuticals

Is Alnylam Pharmaceuticals getting weaker?: Its latest SEC filing (Jul 30, 2026) got stronger: operating margin rose 7.3 points to 20.8%. Its overall score is 67/100, up 3 since Oct 28, 2026.
How is Alnylam Pharmaceuticals valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 60/100 against 1,393 healthcare peers. Earnings yield 3.6% vs a peer median of 1.5% (stronger than 67% of peers).Earnings yield 3.6% vs peers 1.5% (stronger than 67% of peers).
Is Alnylam Pharmaceuticals growing?: Yes, faster than most of its peers. Growth scores 97/100 against 1,393 healthcare peers. Revenue growth 95.1% vs a peer median of 6.1% (stronger than 94% of peers).Revenue growth 95.1% vs peers 6.1% (stronger than 94% of peers).
How profitable is Alnylam Pharmaceuticals?: More profitable than most of its peers. Profitability scores 97/100 against 1,393 healthcare peers. Return on invested capital 65.8% vs a peer median of 4.7% (stronger than 95% of peers).Return on invested capital 65.8% vs peers 4.7% (stronger than 95% of peers).
How risky is Alnylam Pharmaceuticals?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.27 vs a peer median of 0.63 (stronger than 83% of peers).Beta 0.27 vs peers 0.63 (stronger than 83% of peers). Debt / equity 2.21× vs a peer median of 0.22× (weaker than 90% of peers).Debt / equity 2.21× vs peers 0.22× (weaker than 90% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Jul 30, 2026 · compared with the quarter ended Dec 31, 2025

Got stronger

Operating margin rose 7.3 points to 20.8%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	3.7B USD	4.8B USD	+29.4%
Net income (12 months)	313.7M USD	774.7M USD	+146.9%
Operating margin	13.5%	20.8%	+7.3 pts
Free cash flow (12 months)	465.4M USD	819.9M USD	+76.2%
Cash	1.7B USD	1.7B USD	+3.1%
Shares outstanding	132.6M	133.8M	+0.9%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	86.4%	86.5%	85.3%	86.4%	81.8%	▼ 4.6 pts
Operating margin	-83.9%	-75.7%	-15.4%	-7.9%	13.5%	▲ 21 pts
Net margin	-101.0%	-109.0%	-24.1%	-12.4%	8.4%	▲ 21 pts
Return on assets (ROA)	-23.4%	-31.9%	-11.5%	-6.6%	6.3%	▲ 13 pts
Return on equity (ROE)	-145.0%	—	—	—	39.8%	—
Free cash flow margin	-85.0%	-59.1%	2.3%	-1.9%	12.5%	▲ 14 pts
Current ratio	4.04×	3.51×	3.08×	2.78×	2.76×	▼ 0.6%
Quick ratio	3.91×	3.34×	2.99×	2.71×	2.71×	▼ 0.2%
Interest coverage	-4.95×	-5.03×	-2.33×	-1.25×	1.99×	▲ 259%

ALNY price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings

Drawback: higher risk than most peers: more debt relative to equity (2.21× vs a peer median of 0.22×)higher risk: more debt vs equity (2.21× vs peers 0.22×)

Ranks #194 of 1,157 healthcare companies (top 17%)

See how it ranks against its peers

Worth knowing

Earnings turned from a loss to a profit. Profit per share this year after a loss last year.

Alnylam Pharmaceuticals made a profit per share in its latest year after a loss the year before.

Operating margin at a 6-year high. 14% in 2025, the best of the last 6 years.

Alnylam Pharmaceuticals kept 14% of revenue as operating profit in 2025, its highest in the 6 years of filings we have.

Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $493M in 2020 to $3.7B in 2025.

Alnylam Pharmaceuticals's fiscal-year revenue rose in each of the five years to 2025, from $493M to $3.7B.

Profit is backed by cash. Free cash flow is 106% of reported profit.

Alnylam Pharmaceuticals's free cash flow is 106% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

Questions investors ask about Alnylam Pharmaceuticals

Is Alnylam Pharmaceuticals getting weaker?

Its latest SEC filing (Jul 30, 2026) got stronger: operating margin rose 7.3 points to 20.8%. Its overall score is 67/100, up 3 since Oct 28, 2026.

How is Alnylam Pharmaceuticals valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 60/100 against 1,393 healthcare peers. Earnings yield 3.6% vs a peer median of 1.5% (stronger than 67% of peers).Earnings yield 3.6% vs peers 1.5% (stronger than 67% of peers).

Is Alnylam Pharmaceuticals growing?

Yes, faster than most of its peers. Growth scores 97/100 against 1,393 healthcare peers. Revenue growth 95.1% vs a peer median of 6.1% (stronger than 94% of peers).Revenue growth 95.1% vs peers 6.1% (stronger than 94% of peers).

How profitable is Alnylam Pharmaceuticals?

More profitable than most of its peers. Profitability scores 97/100 against 1,393 healthcare peers. Return on invested capital 65.8% vs a peer median of 4.7% (stronger than 95% of peers).Return on invested capital 65.8% vs peers 4.7% (stronger than 95% of peers).

How risky is Alnylam Pharmaceuticals?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.27 vs a peer median of 0.63 (stronger than 83% of peers).Beta 0.27 vs peers 0.63 (stronger than 83% of peers). Debt / equity 2.21× vs a peer median of 0.22× (weaker than 90% of peers).Debt / equity 2.21× vs peers 0.22× (weaker than 90% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

3.7B USD

4.8B USD

+29.4%

Net income (12 months)

313.7M USD

774.7M USD

+146.9%

Operating margin

13.5%

20.8%

+7.3 pts

Free cash flow (12 months)

465.4M USD

819.9M USD

+76.2%

Cash

1.7B USD

1.7B USD

+3.1%

Shares outstanding

132.6M

133.8M

+0.9%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

86.4%

86.5%

85.3%

86.4%

81.8%

▼ 4.6 pts

Operating margin

-83.9%

-75.7%

-15.4%

-7.9%

13.5%

▲ 21 pts

Net margin

-101.0%

-109.0%

-24.1%

-12.4%

8.4%

▲ 21 pts

Return on assets (ROA)

-23.4%

-31.9%

-11.5%

-6.6%

6.3%

▲ 13 pts

Return on equity (ROE)

-145.0%

—

39.8%

—

Free cash flow margin

-85.0%

-59.1%

2.3%

-1.9%

12.5%

▲ 14 pts

Current ratio

4.04×

3.51×

3.08×

2.78×

2.76×

▼ 0.6%

Quick ratio

3.91×

3.34×

2.99×

2.71×

▼ 0.2%

Interest coverage

-4.95×

-5.03×

-2.33×

-1.25×

1.99×

▲ 259%